Drugs under investigation for attention-deficit hyperactivity disorder

Julie B Schweitzer, Henry H. Holcomb

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


There has been substantial development of pharmacological treatments for attention-deficit hyperactivity disorder (ADHD) recently. The greatest change is the approval of new delivery systems for methylphenidate (MPH) and amphetamine (AMP) that permit once a day dosing. There are also a number of new compounds under development for the disorder, including several non-stimulant agents. These compounds target the noradrenergic, histaminergic and dopaminergic systems. The recent developments in the pharmacological treatment of ADHD should increase therapeutic options and the percentage of individuals with the disorder who can be effectively treated.

Original languageEnglish (US)
Pages (from-to)1207-1211
Number of pages5
JournalCurrent Opinion in Investigational Drugs
Issue number8
StatePublished - Aug 1 2002
Externally publishedYes


  • ADHD
  • Non-stimulant
  • Psychopharmacology
  • Stimulant

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Drugs under investigation for attention-deficit hyperactivity disorder'. Together they form a unique fingerprint.

Cite this